Ticker brief

ARQT

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
7
crowd 14d
+0.1σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Options inteloptions-surface reads · latest available day per source
metricreadingcontext
OI alarmquietlast alarm 2024-12-26 (z=4.1)
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-15 · now +0.13 (−1 bearish … +1 bullish)
Who spoke7
authorgradetrader scoresignalsmean sent
@BiopharmIQB·2+0.18
@Quantumup1C+0.101+0.40
@CrweWorldC·1+0.10
@bullishchartC-1.211+0.55
@CHItraderB-0.221+0.40
@OpenOutcrierC·1+0.00
@equityddC-1.081+0.00
Recent signals8of 8 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-15@equitydd+0.00Lists stocks making large moves without specifying direction in text.·
2026-10-15@OpenOutcrier+0.00Lists October 15 analyst coverage initiations without ratings or firms.·
2026-10-15@CHItrader+0.40Lists multiple bullish sell-side coverage initiations; output is capped at six tickers.·
2026-10-09@bullishchart+0.55Reports rapid disease clearance in an infant atopic dermatitis trial and a bullish RSI scan.·
2026-10-09@BiopharmIQ+0.20Biotech news-and-mover list covering regulatory, enrollment, and data events; ticker list capped at six.·
2026-10-09@CrweWorld+0.10Arcutis announced presentations of ZORYVE and corticosteroid research data at conferences.·
2026-10-08@Quantumup1+0.40Jefferies reiterated Buy with a $39 target and detailed sales estimates.·
2026-10-04@BiopharmIQ+0.15Flags expected Q4 Phase 2 vitiligo results and a program-advancement decision for ZORYVE foam.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.